Present and future of PET radiopharmaceuticals. Elsinga P. Nucl Med Review 2012. 15 Supp C13-C16
New PET radiopharmaceuticals beyond FDG for brain tumor imaging.
Gulyás B1, Halldin CQ J Nucl Med Mol Imaging. 2012 Apr;56(2):173-90.
Synthesis of oncological [11C]radiopharmaceuticals for clinical PET
Lodi F, Malizia C, Castellucci P, Cicoria G, Fanti S, Boschi S. Nucl Med Biol. 2012 May;39(4):447-60. Synthesis of oncological [11C]radiopharmaceuticals for clinical PET.
Basis and principles of radiopharmaceuticals for PET/CT. Wadsak W, Mitterhauser M. Eur J Radiol. 2010;73(3):461-469
Stability of 11C-labeled PET radiopharmaceuticals.
Fukumura T, Nakao R, Yamaguchi M, Suzuki K. Appl Radiat Isot. 2004 Dec;61(6):1279-87.
Radiofármacos PET. Peñuelas I. Rev Esp Med Nucl. 2001;20(3):477-98
Radioembolization with 90Y-microspheres for liver tumors
Radioembolization in liver tumours
18F-fluorodeoxyglucose positron emission tomography in the diagnosis of malignancy in patients with paraneoplastic neurological syndrome: a systematic review and meta-analysis.
García Vicente AM, Delgado-Bolton R, Amo-Salas M, López-Fidalgo J, Caresia Aróztegui AP, García Garzón JR, Orcajo Rincón J, García Velloso MJ, de Arcocha Torres M, Álvarez Ruíz S. Eur J Nucl Med Mol Imaging. 2017; 44(9):1575-1587.
PET/TC con 68Ga-PSMA en el cáncer de próstata. Rev Esp Med Nucl Imagen Mol. 2018 Mar – Apr;37(2):130-138. DOI: 10.1016/j.remn.2017.07.004
José Ramón García, María de arcocha torres, Roberto Delgado-Bolton, Francesco Ceci, Soledad Álvarez, Javier Orcajo Rincón, Ana Paula Caresia, María José Garcia-Velloso, Ana María García Vicente.